Eight virus types cause almost all cervical cancer

	Tweet

Scientists have identified the eight human papillomavirus (HPV) types responsible for more than 90 percent of cervical cancer cases worldwide and say they should be the targets for the next generation of vaccines.

Drugmakers GlaxoSmithKline and Merck & Co. already make vaccines against HPV strains that cause many cases of cervical cancer, which is the second most common cancer in women worldwide and is expected to kill 328,000 this year.

In a large study looking at 60 years of data from 10,575 cases of invasive cervical cancer across 38 countries, an international team of scientists led by Silvia de Sanjose of the Catalan Institute of Oncology in Barcelona examined which types of HPV contributed most to the global incidence of the disease.

Their results, published in the Lancet Oncology medical journal on Monday, showed that eight HPV types - types 16, 18, 45, 33, 31, 52, 58, and 35, in descending order of frequency - were responsible for more than 90 percent of cases.

GSK’s vaccine Cervarix and Merck’s Gardasil protect against HPV types 16 and 18, and, through cross-protection, partially also against HPV types 31 and 45.

Many wealthy countries have started HPV immunization programs with these shots for girls before they become sexually active, but the vaccines are generally too expensive and inaccessible for most people living in poorer nations.

De Sanjose said the study’s findings reinforced “the rationale for prevention of cervical cancer through use of existing vaccines” and would aid the development of second-generation vaccines against multiple HPV types.

Around 80 percent of the world’s cervical cancer cases now occur in developing countries and the disease is caused by high-risk and sexually transmitted types of HPV.

Of the more than 118 different HPV types that have been identified, about 40 infect the genital tract and 12 are known to be cancer-causing, the scientists explained.

In their study, which involved cancer cases from Europe, North America, central South America, Africa, Asia, and Oceania, the researchers also identified several rare HPV types - types 26, 30, 61, 67, 69, 82, and 91 - which can also cause cervical cancer but account for only one percent of cases worldwide.

In a written commentary about the study, Cosette Wheeler of the University of New Mexico Health Sciences Center in the United States described the research as “a Herculean effort that might be the benchmark for all time.”

The results “clearly support future directions for cervical screening and type-specific triage, establish the potential worldwide impact of current HPV vaccines, and set priorities for next-generation vaccines,” she wrote.

SOURCE: The Lancet Oncology, online October 18, 2010.

RELATED STORIES:
Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia   Cervical cancer chemo easier on black women: study   Protein found to be the link missing between HPV infection and cervical cancer development   Obese women in Canada are less likely to be screened for cervical cancer   HIV drug stops cervical cancer in laboratory test   Aggressive vaccine effort could cut cervical cancer   US FDA approves Hycamtin for cervical cancer   Newer cervical cancer test no better than the old?   New cervical cancer vaccine offers women 100% protection   Vaccine no replacement for Pap test   Hysterectomy for cervical cancer feasible in obese women   Phone counseling improves quality of life, immune systems of cervical cancer survivors   Merck says US CDC endorses cervical cancer vaccine   Post-treatment PET Scans Can Reassure Cervical Cancer Patients   Genetic Differences Help Protect Against Cervical Cancer   Study indicates vaccine prevents cervical cancer   Urinary tract cancer associated with Chinese herbal products containing aristolochic acid   Girls should get cervical cancer vaccine, panel says   Aspirin Merits Testing for Prevention of Cervical Cancer in HIV-Infected Women   Stress May Increase a Woman’s Risk of Developing Cervical Cancer   Glaxo HPV vaccine shows promise for women 26-55   Cervical disease sufferers could benefit from HPV vaccine

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]